Cargando…

The Vaccine World of COVID-19: India’s Contribution

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not only illness and mortality in its wake, but also an overwhelming threat to health policy, human regality, food security, and struggle worldwide. The accessibility and potential distribution of a protective and suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavda, Vivek P., Vihol, Disha R., Solanki, Hetvi K., Apostolopoulos, Vasso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695423/
https://www.ncbi.nlm.nih.gov/pubmed/36423038
http://dx.doi.org/10.3390/vaccines10111943
_version_ 1784838056329609216
author Chavda, Vivek P.
Vihol, Disha R.
Solanki, Hetvi K.
Apostolopoulos, Vasso
author_facet Chavda, Vivek P.
Vihol, Disha R.
Solanki, Hetvi K.
Apostolopoulos, Vasso
author_sort Chavda, Vivek P.
collection PubMed
description The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not only illness and mortality in its wake, but also an overwhelming threat to health policy, human regality, food security, and struggle worldwide. The accessibility and potential distribution of a protective and successful vaccination to communities throughout the world are being considered now not just, as a potential of overcoming these hurdles, but also as an example of human perseverance in the face of catastrophe. A vaccine is the only tool that can efficaciously deal with the COVID-19 catastrophe. Currently, more than 47 vaccines are permitted for emergency use in distinct parts of the world. India will play a significant role in the development of the high-priced Moderna shots and Pfizer Inc, therefore assisting in the immunization of a large portion of the world. Moreover, many of the internationally researched and developed vaccine laboratories seek manufacturing in Indian firms and companies for efficient and low-cost production of vaccines intending to provide to the world, hence, making India, a major role player during these pandemic times. This review highlights the Indian contribution to the globe for COVID-19 management.
format Online
Article
Text
id pubmed-9695423
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96954232022-11-26 The Vaccine World of COVID-19: India’s Contribution Chavda, Vivek P. Vihol, Disha R. Solanki, Hetvi K. Apostolopoulos, Vasso Vaccines (Basel) Review The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not only illness and mortality in its wake, but also an overwhelming threat to health policy, human regality, food security, and struggle worldwide. The accessibility and potential distribution of a protective and successful vaccination to communities throughout the world are being considered now not just, as a potential of overcoming these hurdles, but also as an example of human perseverance in the face of catastrophe. A vaccine is the only tool that can efficaciously deal with the COVID-19 catastrophe. Currently, more than 47 vaccines are permitted for emergency use in distinct parts of the world. India will play a significant role in the development of the high-priced Moderna shots and Pfizer Inc, therefore assisting in the immunization of a large portion of the world. Moreover, many of the internationally researched and developed vaccine laboratories seek manufacturing in Indian firms and companies for efficient and low-cost production of vaccines intending to provide to the world, hence, making India, a major role player during these pandemic times. This review highlights the Indian contribution to the globe for COVID-19 management. MDPI 2022-11-17 /pmc/articles/PMC9695423/ /pubmed/36423038 http://dx.doi.org/10.3390/vaccines10111943 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chavda, Vivek P.
Vihol, Disha R.
Solanki, Hetvi K.
Apostolopoulos, Vasso
The Vaccine World of COVID-19: India’s Contribution
title The Vaccine World of COVID-19: India’s Contribution
title_full The Vaccine World of COVID-19: India’s Contribution
title_fullStr The Vaccine World of COVID-19: India’s Contribution
title_full_unstemmed The Vaccine World of COVID-19: India’s Contribution
title_short The Vaccine World of COVID-19: India’s Contribution
title_sort vaccine world of covid-19: india’s contribution
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695423/
https://www.ncbi.nlm.nih.gov/pubmed/36423038
http://dx.doi.org/10.3390/vaccines10111943
work_keys_str_mv AT chavdavivekp thevaccineworldofcovid19indiascontribution
AT viholdishar thevaccineworldofcovid19indiascontribution
AT solankihetvik thevaccineworldofcovid19indiascontribution
AT apostolopoulosvasso thevaccineworldofcovid19indiascontribution
AT chavdavivekp vaccineworldofcovid19indiascontribution
AT viholdishar vaccineworldofcovid19indiascontribution
AT solankihetvik vaccineworldofcovid19indiascontribution
AT apostolopoulosvasso vaccineworldofcovid19indiascontribution